Skip to main content
AAN.com

Abstract

Background: The most frequent phenotypes of dysferlin myopathy are limb-girdle muscular dystrophy 2B (LGMD2B) and Miyoshi myopathy (MM). Our objective was to find clinical or MRI markers to differentiate phenotypes of dysferlin myopathy regardless of initial symptoms.
Methods: This retrospective study included 29 patients with confirmed mutations in the DYSF gene (14 MM, 12 LGMD2B, 1 asymptomatic hyperCKemia, and 2 symptomatic carriers). All underwent an annual clinical examination (Medical Research Council scale), functional status assessment, and creatine kinase, pulmonary, and cardiac testing. For research purposes, we performed lower limb MRI studies in all 29 patients to identify the pattern of muscle impairment and to quantify involvement. Statistical correlations between MRI findings and phenotype, disease duration, and functional status were determined.
Results: The mean clinical follow-up was 6.4 ± 5.7 years. No significant differences were found in the rate of progression, functional prognosis, or mutations between patients with MM and patients with LGMD2B. The MRI pattern of muscle involvement was the same for patients with MM and patients with LGMD2B. The adductor magnus and gastrocnemius medialis were the first to be impaired in both phenotypes. The progression of muscle involvement correlated with clinical status.
Conclusions: Splitting dysferlin myopathy into separate phenotypes does not reveal significant differences in terms of rate of progression, prognosis, genotype, or MRI pattern. The finding that proximal and distal muscles are already impaired in the MRI at onset in both MM and LGMD2B favors grouping all phenotypes under the term dysferlin myopathy.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (figure_e-1.doc)
File (figure_e-2.doc)
File (table_e-1.doc)

REFERENCES

1.
Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998;20:31–36.
2.
Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998;20:37–42.
3.
Miyoshi K, Iwasa M, Kawai H, et al. Autosomal recessive distal muscular dystrophy: a new type of distal muscular dystrophy observed characteristically in Japan. Jpn J Clin Med 1977;35:3922–3928.
4.
Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR, et al. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 2000;55:1931–1933.
5.
Vilchez JJ, Gallano P, Gallardo E, et al. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Arch Neurol 2005;62:1256–1259.
6.
Illa I, Serrano-Munuera C, Gallardo E, et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001;49:130–134.
7.
Nguyen K, Bassez G, Krahn M, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64:1176–1182.
8.
Klinge L, Dean AF, Kress W, et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord 2008;18:288–290.
9.
Paradas C, González-Quereda L, De Luna N, et al. A new phenotype of dysferlinopathy with congenital onset. Neuromuscul Disord 2009;19:21–26.
10.
Illa I, De Luna N, Dominguez-Perles R, et al. Symptomatic dysferlin gene mutation carriers: characterization of two cases. Neurology 2007;68:1284–1289.
11.
Argov Z, Sadeh M, Mazor K, et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews: clinical and genetic features. Brain 2000;123:1229–1237.
12.
Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat 2005;26:165.
13.
Takahashi T, Aoki M, Tateyama M, et al. Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology 2003;60:1799–1804.
14.
Marden FA, Connolly AM, Siegel MJ, Rubin DA. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 2005;34:140–148.
15.
Mercuri E, Bushby K, Ricci E, et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005;15:164–171.
16.
Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 2007;25:433–440.
17.
Fischer D, Herasse M, Ferreiro A, et al. Muscle imaging in dominant core myopathies linked or unlinked to the ryanodine receptor 1 gene. Neurology 2006;67:2217–2220.
18.
Jungbluth H, Sewry CA, Counsell S, et al. Magnetic resonance imaging of muscle in nemaline myopathy. Neuromuscul Disord 2004;14:779–784.
19.
Cupler EJ, Bohlega S, Hessler R, McLean D, Stigsby B, Ahmad J. Miyoshi myopathy in Saudi Arabia: clinical, electrophysiological, histopathological and radiological features. Neuromuscul Disord 1998;8:321–326.
20.
Flachenecker P, Kiefer R, Naumann M, Handwerker M, Reichmann H. Distal muscular dystrophy of Miyoshi type: report of two cases and review of the literature. J Neurol 1997;244:23–29.
21.
Fischer D, Walter MC, Kesper K, et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 2005;252:538–547.
22.
Meola G, Sansone V, Rotondo G, Jabbour A. Computerized tomography and magnetic resonance muscle imaging in Miyoshi's myopathy. Muscle Nerve 1996;19:1476–1480.
23.
Anderson LV, Davison K. Multiplex Western blotting system for the analysis of muscular dystrophy proteins. Am J Pathol 1999;154:1017–1022.
24.
Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I, Brown Jr RH. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002;51:129–133.
25.
Personius KE, Pandya S, King WM, Tawil R, McDermott MP. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements: The FSH DY Group. Phys Ther 1994;74:253–263.
26.
Tawil R, McDermott MP, Mendell JR, Kissel J, Griggs RC. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing: FSH-DY Group. Neurology 1994;44:442–446.
27.
Guglieri M, Magri F, D'Angelo MG, et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008;29:258–266.
28.
van der Kooi AJ, Frankhuizen WS, Barth PG, et al. Limb-girdle muscular dystrophy in the Netherlands: gene defect identified in half the families. Neurology 2007;68:2125–2128.
29.
Anderson LV, Harrison RM, Pogue R, et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000;10:553–559.
30.
Huang Y, de Morree A, van Remoortere A, et al. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 2008;15:17:1855–1866.
31.
Pradhan S. Diamond on quadriceps: a frequent sign in dysferlinopathy. Neurology 2008;70:322.
32.
Fischer D, Kley RA, Strach K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 2008;71:758–765.
33.
Lamminen AE. Magnetic resonance imaging of primary skeletal muscle diseases: patterns of distribution and severity of involvement. Br J Radiol 1990;63:946–950.
34.
Mercuri E, Lampe A, Allsop J, et al. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscul Disord 2005;15:303–310.
35.
Berciano J, Gallardo E, Garcia A, Combarros O. Pes cavus pathogenesis in Charcot-Marie-Tooth disease type 1A. Brain 2006;129:E51.
36.
Mahjneh I, Marconi G, Bushby K, Anderson LV, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord 2001;11:20–26.
37.
Linssen WH, Notermans NC, Van der Graaf Y, et al. Miyoshi-type distal muscular dystrophy: clinical spectrum in 24 Dutch patients. Brain 1997;120:1989–1996.

Information & Authors

Information

Published In

Neurology®
Volume 75Number 4July 27, 2010
Pages: 316-323
PubMed: 20574037

Publication History

Published online: June 23, 2010
Published in print: July 27, 2010

Permissions

Request permissions for this article.

Keyword

  1. CK = creatine kinase; CMMT = composite manual muscle testing score; CMMT-d = composite manual muscle testing score of distal muscles (lower legs); CMMT-g = composite manual muscle testing score of all the muscle groups examined; CMMT-p = composite manual muscle testing score of proximal muscles (thighs); LGMD2B = limb-girdle muscular dystrophy 2B; MM = Miyoshi myopathy; MMT = manual muscle testing; MRC = Medical Research Council; STIR = short-time inversion recovery.

Notes

Authors

Affiliations & Disclosures

C. Paradas, MD, PhD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
J. Llauger, MD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
J. Diaz-Manera, MD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
R. Rojas-García, MD, PhD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
N. De Luna, PhD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
C. Iturriaga, MD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
C. Márquez, MD, PhD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
M. Usón, MD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
K. Hankiewicz, MD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
E. Gallardo, PhD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.
I. Illa, MD, PhD
From the Department of Neurology (C.P., C.M.), Hospital Universitario Virgen del Rocío, Seville; Departments of Radiology (J.L.) and Neurology (J.D.-M., R.R.-G., C.I., K.H., I.I.), Hospital Santa Creu i Sant Pau, Barcelona; Laboratori Neurologia Experimental (N.D., E.G.), Institut Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Neurology (M.U.), Fundación Hospital Son Llatzer, Palma de Mallorca, Spain; Universitat Autònoma de Barcelona (I.I.) and Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED) (C.P., J.D.-M., R.R.-G., N.D., E.G., I.I.), Spain.

Notes

Address correspondence and reprint requests to Dr. Isabel Illa, Department of Neurology, Hospital de la Santa Creu i Sant Pau, C/Pare Claret 167, 08025 Barcelona, Spain [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. A Straightforward Approach to Analyze Skeletal Muscle MRI in Limb-Girdle Muscular Dystrophy for Differential Diagnosis: A Systematic Review, Muscles, 2, 4, (374-388), (2023).https://doi.org/10.3390/muscles2040029
    Crossref
  2. Longitudinal Analysis of Respiratory Function of Different Types of Limb Girdle Muscular Dystrophies Reveals Independent Trajectories, Neurology Genetics, 9, 4, (2023)./doi/10.1212/NXG.0000000000200084
    Abstract
  3. Patterns of Clinical Progression Among Patients With Autosomal Recessive Limb-Girdle Muscular Dystrophy: A Systematic Review, Journal of Clinical Neuromuscular Disease, 25, 2, (65-80), (2023).https://doi.org/10.1097/CND.0000000000000461
    Crossref
  4. Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort, Brain, 146, 9, (3800-3815), (2023).https://doi.org/10.1093/brain/awad088
    Crossref
  5. Magnetic resonance imaging-based criteria to differentiate dysferlinopathy from other genetic muscle diseases, Neuromuscular Disorders, (2023).https://doi.org/10.1016/j.nmd.2023.11.004
    Crossref
  6. Muscle magnetic resonance imaging of a large cohort of distal hereditary motor neuropathies reveals characteristic features useful for diagnosis, Neuromuscular Disorders, 33, 10, (744-753), (2023).https://doi.org/10.1016/j.nmd.2023.08.010
    Crossref
  7. Dysferlinopathy in Tunisia: clinical spectrum, genetic background and prognostic profile, Neuromuscular Disorders, 33, 10, (718-727), (2023).https://doi.org/10.1016/j.nmd.2023.08.007
    Crossref
  8. Expanding the muscle imaging spectrum in dysferlinopathy: description of an outlier population from the classical MRI pattern, Neuromuscular Disorders, 33, 4, (349-357), (2023).https://doi.org/10.1016/j.nmd.2023.02.007
    Crossref
  9. Distal myopathy, Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders, (497-519), (2023).https://doi.org/10.1016/B978-0-323-98818-6.00002-9
    Crossref
  10. Characteristics of the muscle involvement along the disease progression in a large cohort of oculopharyngodistal myopathy compared to oculopharyngeal muscular dystrophy, Journal of Neurology, 270, 12, (5988-5998), (2023).https://doi.org/10.1007/s00415-023-11906-9
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share